Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1999;8(3):159-67.
doi: 10.1080/09629359990496.

Inflammatory markers in cystic fibrosis patients with lung Pseudomonas aeruginosa infection

Affiliations

Inflammatory markers in cystic fibrosis patients with lung Pseudomonas aeruginosa infection

A L Pukhalsky et al. Mediators Inflamm. 1999.

Abstract

Chronic endobronchial inflammation and bacterial infection are the main causes of morbidity and mortality in cystic fibrosis (CF), an autosomal recessive genetic disorder associated with improper function of chloride channels. Inflammation in CF lung is greatly amplified after Pseudomonas aeruginosa infection. In this study the relationship between P. aeruginosa status and inflammatory markers has been investigated. Seventeen CF children in acute lung exacerbation were examined. CF patients without P. aeruginosa infection were characterized by elevated activity of sputum elastase, reduced response of peripheral blood lymphocytes to PHA and significant resistance to the antiproliferative action of glucocorticoids. These parameters were normalized after antibiotic treatment. The patients with prolonged P. aeruginosa infection demonstrated extremely high levels of elastase activity and elevated amounts of sputum IL-8 and TNF-alpha. Although antibiotic treatment resulted in clinical improvement, it failed to suppress excessive immune response in the lung. The data indicate that CF patients with prolonged P. aeruginosa need the modified treatment, which should include immunomodulating drugs and protease inhibitors as well as antibacterial therapy.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Eur Respir J. 1993 Nov;6(10):1429-36 - PubMed
    1. Eur Respir J. 1993 Oct;6(9):1243-8 - PubMed
    1. Cell. 1996 Apr 19;85(2):229-36 - PubMed
    1. Microbiol Rev. 1996 Sep;60(3):539-74 - PubMed
    1. Annu Rev Microbiol. 1996;50:727-51 - PubMed

MeSH terms